Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
10,154
archived clinical trials in
Other Indications

The Variability of 25-hydroxyvitamin D Response From Crystalline 25-hydroxyvitamin D3
The Variability of 25-hydroxyvitamin D Response From Crystalline 25-hydroxyvitamin D3 Compared to Native Vitamin D3: A Short Term Pharmacokinetic Study
Status: Enrolling
Updated:  7/3/2012
Creighton University
mi
from
Omaha, NE
The Variability of 25-hydroxyvitamin D Response From Crystalline 25-hydroxyvitamin D3
The Variability of 25-hydroxyvitamin D Response From Crystalline 25-hydroxyvitamin D3 Compared to Native Vitamin D3: A Short Term Pharmacokinetic Study
Status: Enrolling
Updated: 7/3/2012
Creighton University
mi
from
Omaha, NE
Click here to add this to my saved trials
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
Status: Enrolling
Updated:  7/6/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
Status: Enrolling
Updated: 7/6/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy.
Status: Enrolling
Updated:  7/10/2012
University of Texas Hlth Sci Ctr San Ant
mi
from
San Antonio, TX
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy.
Status: Enrolling
Updated: 7/10/2012
University of Texas Hlth Sci Ctr San Ant
mi
from
San Antonio, TX
Click here to add this to my saved trials
Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)
To Evaluate Bacteriophage OX174 Antigen as a Useful Immunogen in Patients With Immune Deficiency
Status: Enrolling
Updated:  7/16/2012
University of South Florida
mi
from
St. Petersburg, FL
Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)
To Evaluate Bacteriophage OX174 Antigen as a Useful Immunogen in Patients With Immune Deficiency
Status: Enrolling
Updated: 7/16/2012
University of South Florida
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Highlands Oncology Group
mi
from
Springdale, AR
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Highlands Oncology Group
mi
from
Springdale, AR
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Hematology Oncology Services of Arkansas Dept. of HOSA
mi
from
Little Rock, AR
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Hematology Oncology Services of Arkansas Dept. of HOSA
mi
from
Little Rock, AR
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
USC Norris Cancer Center/LAC USC Medical Center
mi
from
Los Angeles, CA
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
USC Norris Cancer Center/LAC USC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Southwest Cancer Care Murrieta
mi
from
Poway, CA
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Southwest Cancer Care Murrieta
mi
from
Poway, CA
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Rocky Mountain Cancer Centers RMCC - Aurora
mi
from
Greenwood Village, CO
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Rocky Mountain Cancer Centers RMCC - Aurora
mi
from
Greenwood Village, CO
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Florida Cancer Institute
mi
from
New Port Richey, FL
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Florida Cancer Institute
mi
from
New Port Richey, FL
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Cancer Centers of Florida PA Cancer Centers of FL-Orlando-4
mi
from
Ocoee, FL
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Cancer Centers of Florida PA Cancer Centers of FL-Orlando-4
mi
from
Ocoee, FL
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Stroger Cook County Hospital John H. Stroger Hospital
mi
from
Chicago, IL
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Stroger Cook County Hospital John H. Stroger Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
St. Francis Hospital and Health Centers IndianaBlood&MarrowTransplantn
mi
from
Beech Grove, IN
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
St. Francis Hospital and Health Centers IndianaBlood&MarrowTransplantn
mi
from
Beech Grove, IN
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Hematology Oncology of Indiana
mi
from
Indianapolis, IN
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Hematology Oncology of Indiana
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE LSU Health Sciences Shreveport
mi
from
New Orleans, LA
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE LSU Health Sciences Shreveport
mi
from
New Orleans, LA
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
St. Agnes Hospital
mi
from
Baltimore, MD
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
St. Agnes Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
St. Louis University Cancer Center
mi
from
St Louis, MO
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
St. Louis University Cancer Center
mi
from
St Louis, MO
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Comprehensive Cancer Centers of Nevada CCC of Nevada (1)
mi
from
Las Vegas, NV
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Comprehensive Cancer Centers of Nevada CCC of Nevada (1)
mi
from
Las Vegas, NV
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Hematology Oncology Associates of Northern New Jersey PA Dept of Hem-Onc of Northern NJ
mi
from
Morristown, NJ
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Hematology Oncology Associates of Northern New Jersey PA Dept of Hem-Onc of Northern NJ
mi
from
Morristown, NJ
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Interlakes Oncology/Hematology PC
mi
from
Rochester, NY
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Interlakes Oncology/Hematology PC
mi
from
Rochester, NY
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Cancer Centers of North Carolina Cancer Centers of NC-Raleigh
mi
from
Raleigh, NC
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Cancer Centers of North Carolina Cancer Centers of NC-Raleigh
mi
from
Raleigh, NC
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Northwest Cancer Specialists Salmon Creek Office
mi
from
Portland, OR
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Northwest Cancer Specialists Salmon Creek Office
mi
from
Portland, OR
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Oregon Health Sciences University
mi
from
Portland, OR
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Oregon Health Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
The Jones Clinic
mi
from
Memphis, TN
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
The Jones Clinic
mi
from
Memphis, TN
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Texas Oncology, P.A.
mi
from
Bedford, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Texas Oncology, P.A.
mi
from
Bedford, TX
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Texas Oncology, P.A. Texas Oncology - Sugar Land
mi
from
Dallas, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Texas Oncology, P.A. Texas Oncology - Sugar Land
mi
from
Dallas, TX
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp
mi
from
Dallas, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp
mi
from
Dallas, TX
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
MD Anderson Cancer Center/University of Texas
mi
from
Houston, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
MD Anderson Cancer Center/University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Baylor College of Medicine Baylor College of Medicine (3)
mi
from
Houston, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Baylor College of Medicine Baylor College of Medicine (3)
mi
from
Houston, TX
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)
mi
from
San Antonio, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated:  7/19/2012
Cancer Care Centers of South Texas / HOAST CCC of So.TX- MedicalCenter(2)
mi
from
San Antonio, TX
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Status: Enrolling
Updated: 7/19/2012
Cancer Care Centers of South Texas / HOAST CCC of So.TX- MedicalCenter(2)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Green Tea Lozenges for the Management of Dry Mouth
A Natural Formulation for Patients Diagnosed With Xerostomia
Status: Enrolling
Updated:  7/23/2012
GHSU Center for Oral Medicine
mi
from
Augusta, GA
Green Tea Lozenges for the Management of Dry Mouth
A Natural Formulation for Patients Diagnosed With Xerostomia
Status: Enrolling
Updated: 7/23/2012
GHSU Center for Oral Medicine
mi
from
Augusta, GA
Click here to add this to my saved trials
Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease
Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease
Status: Enrolling
Updated:  7/24/2012
Rush University Medical Center
mi
from
Chicago, IL
Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease
Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease
Status: Enrolling
Updated: 7/24/2012
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study for Patients With Acute Leukemia
Phase 1 Study of LY2523355 in Patients With Acute Leukemia
Status: Enrolling
Updated:  8/1/2012
Clinical Research Facility
mi
from
Chicago, IL
A Study for Patients With Acute Leukemia
Phase 1 Study of LY2523355 in Patients With Acute Leukemia
Status: Enrolling
Updated: 8/1/2012
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study for Patients With Acute Leukemia
Phase 1 Study of LY2523355 in Patients With Acute Leukemia
Status: Enrolling
Updated:  8/1/2012
Clinical Research Facility
mi
from
Indianapolis, IN
A Study for Patients With Acute Leukemia
Phase 1 Study of LY2523355 in Patients With Acute Leukemia
Status: Enrolling
Updated: 8/1/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study for Patients With Acute Leukemia
Phase 1 Study of LY2523355 in Patients With Acute Leukemia
Status: Enrolling
Updated:  8/1/2012
Clinical Research Facility
mi
from
Boston, MA
A Study for Patients With Acute Leukemia
Phase 1 Study of LY2523355 in Patients With Acute Leukemia
Status: Enrolling
Updated: 8/1/2012
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study for Patients With Acute Leukemia
Phase 1 Study of LY2523355 in Patients With Acute Leukemia
Status: Enrolling
Updated:  8/1/2012
Clinical Research Facility
mi
from
Nashville, TN
A Study for Patients With Acute Leukemia
Phase 1 Study of LY2523355 in Patients With Acute Leukemia
Status: Enrolling
Updated: 8/1/2012
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study for Patients With Acute Leukemia
Phase 1 Study of LY2523355 in Patients With Acute Leukemia
Status: Enrolling
Updated:  8/1/2012
Clinical Research Facility
mi
from
Houston, TX
A Study for Patients With Acute Leukemia
Phase 1 Study of LY2523355 in Patients With Acute Leukemia
Status: Enrolling
Updated: 8/1/2012
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation
Status: Enrolling
Updated:  8/5/2012
Duke University Medical Center Pediatric Blood and Marrow Transplant Program
mi
from
Durham, NC
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation
Status: Enrolling
Updated: 8/5/2012
Duke University Medical Center Pediatric Blood and Marrow Transplant Program
mi
from
Durham, NC
Click here to add this to my saved trials
Comparison of Wound Bed Establishment in Facial Burns
Comparison of Wound Bed Establishment in Facial Burns Using Two Standard Ointments
Status: Enrolling
Updated:  8/16/2012
UofL Health Care
mi
from
Louisville, KY
Comparison of Wound Bed Establishment in Facial Burns
Comparison of Wound Bed Establishment in Facial Burns Using Two Standard Ointments
Status: Enrolling
Updated: 8/16/2012
UofL Health Care
mi
from
Louisville, KY
Click here to add this to my saved trials
Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA)
Continuous Positive Airway Pressure for Fatigue Treatment in Patients With Multiple Sclerosis and Obstructive Sleep Apnea
Status: Enrolling
Updated:  8/20/2012
Northwestern UNiversity, Department of Neurology
mi
from
Chicago, IL
Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA)
Continuous Positive Airway Pressure for Fatigue Treatment in Patients With Multiple Sclerosis and Obstructive Sleep Apnea
Status: Enrolling
Updated: 8/20/2012
Northwestern UNiversity, Department of Neurology
mi
from
Chicago, IL
Click here to add this to my saved trials
Multi-Site Evaluation of Progressive Tinnitus Management
Multi-Site Evaluation of Progressive Tinnitus Management
Status: Enrolling
Updated:  8/23/2012
VA Connecticut Health Care System
mi
from
West Haven, CT
Multi-Site Evaluation of Progressive Tinnitus Management
Multi-Site Evaluation of Progressive Tinnitus Management
Status: Enrolling
Updated: 8/23/2012
VA Connecticut Health Care System
mi
from
West Haven, CT
Click here to add this to my saved trials
Multi-Site Evaluation of Progressive Tinnitus Management
Multi-Site Evaluation of Progressive Tinnitus Management
Status: Enrolling
Updated:  8/23/2012
VA Medical Center, Portland
mi
from
Portland, OR
Multi-Site Evaluation of Progressive Tinnitus Management
Multi-Site Evaluation of Progressive Tinnitus Management
Status: Enrolling
Updated: 8/23/2012
VA Medical Center, Portland
mi
from
Portland, OR
Click here to add this to my saved trials
Multi-Site Evaluation of Progressive Tinnitus Management
Multi-Site Evaluation of Progressive Tinnitus Management
Status: Enrolling
Updated:  8/23/2012
VA Medical Center, Memphis
mi
from
Memphis, TN
Multi-Site Evaluation of Progressive Tinnitus Management
Multi-Site Evaluation of Progressive Tinnitus Management
Status: Enrolling
Updated: 8/23/2012
VA Medical Center, Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Pacific Cancer Medical Center
mi
from
Anaheim, CA
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Long Beach Memorial
mi
from
Long Beach, CA
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Long Beach Memorial
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Michael J. Schlutz, M.D., Inc
mi
from
Newport Beach, CA
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Michael J. Schlutz, M.D., Inc
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
Cancer Center of Santa Barbara
mi
from
Santa Barbara, CA
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
Cancer Center of Santa Barbara
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated:  8/23/2012
James R. Berenson, MD, Inc
mi
from
West Hollywood, CA
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma
Status: Enrolling
Updated: 8/23/2012
James R. Berenson, MD, Inc
mi
from
West Hollywood, CA
Click here to add this to my saved trials